BioLineRx (BLRX) Total Non-Current Liabilities (2011 - 2026)

BioLineRx's Total Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $5.4 million for Q4 2025.

• In Q4 2025, Total Non-Current Liabilities fell 45.84% year-over-year to $5.4 million; the TTM figure through Dec 2025 stood at $5.4 million (down 45.84% YoY), while the FY2025 annual figure was $5.4 million, down 45.84% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $5.4 million, down from $6.6 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $25.4 million in Q2 2023, with the low at $1.6 million in Q2 2022.
• The 5-year median for Total Non-Current Liabilities is $8.3 million (2023), against an average of $11.2 million.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities slumped 78.22% in 2022, then jumped 1452.87% in 2023.
• BioLineRx's Total Non-Current Liabilities stood at $3.6 million in 2021, then jumped by 314.62% to $14.9 million in 2022, then slumped by 46.73% to $7.9 million in 2023, then grew by 26.79% to $10.0 million in 2024, then tumbled by 45.84% to $5.4 million in 2025.
• Business Quant data shows BLRX's Total Non-Current Liabilities at $5.4 million in Q4 2025, $6.6 million in Q3 2025, and $7.7 million in Q2 2025.